Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity-Reference-Cited by-同舟云学术

Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity

Published:2020-01 Issue: Volume:37 Page:101468
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Juto Alexander^ORCID,Fink Katharina,Al Nimer Faiez,Piehl Fredrik^ORCID

Funder

Swedish Research Council

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference16 articles.

1. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Ann. Neurol.,2016

2. Cancer risk among swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab., ectrims 2018;Alping;Multiple Scler. J. Berlin, Germany,2018

3. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies;Dunn;Mult. Scler.,2018

4. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis;Granqvist;JAMA Neurol.,2018

5. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N. Engl. J. Med.,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies;Multiple Sclerosis and Related Disorders;2024-05

2. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01

3. The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

4. Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy;Revue Neurologique;2024-04

5. Sex impacts treatment decisions in multiple sclerosis;Journal of Neurology;2024-03-05